Promising Phase 3 Data on DMD Hopeful Givinostat Promising Phase 3 Data on DMD Hopeful Givinostat
Treatment with the investigational agent givinostat has the potential to delay disease progression when added to corticosteroid treatment in ambulatory boys with Duchenne muscular dystrophy.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery Source Type: news
More News: Boys | Brain | Corticosteroid Therapy | Muscular Dystrophy | Neurology | Neurosurgery | Reflex Sympathetic Dystrophy